Production (Stage)
Telomir Pharmaceuticals, Inc.
TELO
$2.07
-$0.03-1.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 24.79% | 51.13% | -309.30% | 76.83% | 32.94% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | 483.29% |
| Total Other Non-Cash Items | -37.24% | -54.38% | -- | -- | -- |
| Change in Net Operating Assets | -158.71% | -18.36% | 266.80% | -215.38% | -201.74% |
| Cash from Operations | -42.47% | 39.57% | 34.17% | 21.48% | -78.38% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -200.00% | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | 100.00% | -177.69% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | 6,381.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -159.23% |
| Cash from Financing | -- | 2,311.73% | -135.42% | -97.46% | 379.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -300.02% | 141.12% | 24.53% | -142.48% | 272,858.33% |